Model-based inference of neutralizing antibody avidities against influenza virus.
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Antibody Affinity
/ immunology
Hemagglutination Inhibition Tests
Hemagglutinin Glycoproteins, Influenza Virus
Humans
Immunogenicity, Vaccine
/ immunology
Influenza A Virus, H1N1 Subtype
Influenza, Human
/ immunology
Models, Immunological
Neutralization Tests
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
03
08
2021
accepted:
03
01
2022
revised:
10
02
2022
pubmed:
1
2
2022
medline:
23
2
2022
entrez:
31
1
2022
Statut:
epublish
Résumé
To assess the response to vaccination, quantity (concentration) and quality (avidity) of neutralizing antibodies are the most important parameters. Specifically, an increase in avidity indicates germinal center formation, which is required for establishing long-term protection. For influenza, the classical hemagglutination inhibition (HI) assay, however, quantifies a combination of both, and to separately determine avidity requires high experimental effort. We developed from first principles a biophysical model of hemagglutination inhibition to infer IgG antibody avidities from measured HI titers and IgG concentrations. The model accurately describes the relationship between neutralizing antibody concentration/avidity and HI titer, and explains quantitative aspects of the HI assay, such as robustness to pipetting errors and detection limit. We applied our model to infer avidities against the pandemic 2009 H1N1 influenza virus in vaccinated patients (n = 45) after hematopoietic stem cell transplantation (HSCT) and validated our results with independent avidity measurements using an enzyme-linked immunosorbent assay with urea elution. Avidities inferred by the model correlated with experimentally determined avidities (ρ = 0.54, 95% CI = [0.31, 0.70], P < 10-4). The model predicted that increases in IgG concentration mainly contribute to the observed HI titer increases in HSCT patients and that immunosuppressive treatment is associated with lower baseline avidities. Since our approach requires only easy-to-establish measurements as input, we anticipate that it will help to disentangle causes for poor vaccination outcomes also in larger patient populations. This study demonstrates that biophysical modelling can provide quantitative insights into agglutination assays and complement experimental measurements to refine antibody response analyses.
Identifiants
pubmed: 35100312
doi: 10.1371/journal.ppat.1010243
pii: PPATHOGENS-D-21-01601
pmc: PMC8830794
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
H1N1 virus hemagglutinin
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010243Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21474-9
pubmed: 23236176
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
FEBS J. 2011 May;278(10):1699-712
pubmed: 21410647
Nature. 1965 Oct 2;208(5005):84-5
pubmed: 5886692
Immunol Rev. 2012 May;247(1):52-63
pubmed: 22500831
Nat Med. 2016 Dec;22(12):1456-1464
pubmed: 27820605
ACS Sens. 2019 Feb 22;4(2):370-378
pubmed: 30623662
Dev Biol (Basel). 2003;115:63-73
pubmed: 15088777
Virology. 2000 Dec 20;278(2):423-35
pubmed: 11118365
Biochemistry. 1989 Oct 17;28(21):8388-96
pubmed: 2605190
Cell Rep. 2019 Oct 29;29(5):1066-1073.e5
pubmed: 31665624
Nat Rev Immunol. 2019 Jun;19(6):383-397
pubmed: 30837674
Clin Chim Acta. 1987 Apr 30;164(2):243-4
pubmed: 3594914
Science. 1941 Jul 4;94(2427):22-3
pubmed: 17777315
J Immunol Methods. 1993 Aug 26;164(1):119-30
pubmed: 8360501
Biochemistry. 1992 Oct 13;31(40):9609-21
pubmed: 1327122
Clin Exp Immunol. 2008 Jan;151(1):42-50
pubmed: 18005364
Arch Virol. 1991;116(1-4):45-56
pubmed: 2001177
J Vis Exp. 2017 Dec 1;(130):
pubmed: 29286466
Lancet Infect Dis. 2009 Aug;9(8):493-504
pubmed: 19628174
Curr Opin Virol. 2016 Apr;17:95-103
pubmed: 26927813
Nat Commun. 2019 Jul 26;10(1):3338
pubmed: 31350391
J Virol. 2018 Feb 26;92(6):
pubmed: 29263254
Nature. 1981 Jan 29;289(5796):366-73
pubmed: 7464906
Vaccines (Basel). 2018 Sep 22;6(4):
pubmed: 30248996
Elife. 2020 Jul 07;9:
pubmed: 32633233
J Gen Virol. 1984 Apr;65 ( Pt 4):799-802
pubmed: 6561234
Virology. 1990 Dec;179(2):768-76
pubmed: 1700542
Front Immunol. 2016 Nov 17;7:507
pubmed: 27909435
Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19123-7
pubmed: 17146053
Virology. 1987 Aug;159(2):288-98
pubmed: 3617501
J Gen Microbiol. 1957 Jun;16(3):668-75
pubmed: 13439151
Open Forum Infect Dis. 2015 May 14;2(2):ofv067
pubmed: 26180823
Vaccine. 2015 Aug 7;33(33):4146-54
pubmed: 26057137
J Infect Dis. 2021 Aug 20;:
pubmed: 34415049
Virology. 1996 Mar 15;217(2):452-8
pubmed: 8610436
BMC Infect Dis. 2019 Feb 14;19(1):164
pubmed: 30764767
Arch Biochem Biophys. 2000 Mar 1;375(1):111-8
pubmed: 10683255
Membranes (Basel). 2017 Sep 29;7(4):
pubmed: 28961212
Nat Rev Immunol. 2015 Mar;15(3):137-48
pubmed: 25656706
Virology. 1989 Nov;173(1):317-22
pubmed: 2815586
Elife. 2021 Nov 17;10:
pubmed: 34787567
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):E5143-8
pubmed: 25404330
Math Biosci. 1992 Apr;109(1):1-10
pubmed: 1591446
Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4592-7
pubmed: 23460696